Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 8Neoplasm Metastasis 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Breast Neoplasms, Male 1Advanced Breast Cancer 1Adenocarcinoma, Follicular 1

Interventions

Fulvestrant 19Letrozole 10Anastrozole 8Capecitabine 5palbociclib 4olaparib 4Paclitaxel 4Injections 4Goserelin 4Docetaxel 4trastuzumab deruxtecan 3pyrotinib 3exemestane 3Vinorelbine 3Aromatase Inhibitors 3toripalimab 2sacituzumab govitecan 2ribociclib 2eribulin 2elacestrant 2dalpiciclib 2abemaciclib 2Trastuzumab 2Gonadotropin-Releasing Hormone 2FCN-437c 2Everolimus 2Dasatinib 2Alpelisib 2Albumin-Bound Paclitaxel 2AZD9833 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Cancer × vandetanib × Breast × Clear all
NCT00494481 2016-09-30

E3 Breast Cancer Taxotere Combination

Sanofi

Phase 2 Completed
64 enrolled 7 charts
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡